HUTCHMED 提交 6-K，附两项 III 期临床数据新闻稿
6-K - HUTCHMED (China) Ltd (0001648257) (Filer)
HUTCHMED (China) Limited 提交 6-K 文件，附有两份新闻稿，涉及在 ESMO Congress 2026 展示的 SAFFRON 全球 III 期数据，以及 ORPATHYS 与 TAGRISSO 联合用于一线 EGFR 突变肺癌的 SANOVO III 期数据。SAFFRON 数据同时发表于《新英格兰医学杂志》。
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
For the Month of October 2026
Commission File Number: 001-37710
HUTCHMED (CHINA) LIMITED
(Translation of registrant’s name into English)
48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ⌧ Form 40-F ◻
HUTCHMED (CHINA) LIMITED
Form 6-K
EXHIBIT INDEX
Exhibit No. | | Description |
| | |
Exhibit 99.1 | | Press release relating to HUTCHMED highlights SAFFRON global phase III data presented at ESMO Congress 2026 and simultaneously published in The New England Journal of Medicine |
Exhibit 99.2 | | Press release relating to HUTCHMED highlights SANOVO phase III data for ORPATHYS® plus TAGRISSO® in first-line EGFR-mutated lung cancer presented at ESMO Congress 2026 |
| | |
| | |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| HUTCHMED (CHINA) LIMITED | |
| | |
| | |
| By: | /s/ Johnny Cheng |
| Name: | Johnny Cheng |
| Title: | Chief Financial Officer |
Date: October 26, 2026
3
来源：SEC EDGAR · 本站存档